No Data
No Data
Ensysce Biosciences Announces Continued Enrollment in PF614-MPAR Trial
Express News | Ensysce Biosciences Announce SInterim Data From Second Trial Evaluating PF614-MPAR Showing A 100mg Dosage Form Provided Overdose Protection
Ensysce Biosciences Regains Compliance With Nasdaq
Ensysce Biosciences Regains Full Nasdaq Compliance
Ensysce Biosciences Regains Full Compliance With Nasdaq
Express News | Ensysce Biosciences Secures Commercial Supplier For PF614-MPAR Overdose Protection Drug, Fully Establishing Supply Chain With GMP Nafamostat From Aurore Life Sciences